GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential
Biomolecules · 20.07.2026 · 16 (7) · 1060
DOI: 10.3390/biom16071060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 20.07.2026. Verfasst von Xinyun Gan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Zunyi Medical University, Zunyi 563000, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Growth Differentiation Factor 15. Die Arbeit nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the "12345 Future Talent Training Plan" of Zunyi Medical University, the Guizhou Provincial Natural Science Foundation.
Abstract (Originalsprache)
Liver fibrosis is a chronic pathological process driven by the activation of hepatic stellate cell (HSC) and characterized by the excessive deposition of extracellular matrix (ECM) components in response to persistent liver injury. This condition can lead to progressive hepatic dysfunction, cirrhosis, and ultimately liver failure. Growth differentiation factor 15 (GDF15) has emerged as a pivotal regulator in the initiation and progression of liver fibrosis, exhibiting context-dependent profibrotic and antifibrotic effects. GDF15 modulates multiple cellular processes, including HSC activation and macrophage polarization, as well as the functions of T cells, natural killer cells, B cells and mesenchymal stem cells. This review provides a comprehensive overview of the role of GDF15 in regulating HSC activation and immune cell responses and elaborates on its immunomodulatory functions in attenuating liver fibrosis. Furthermore, we discuss the therapeutic potential of targeting GDF15 for the treatment of liver fibrosis. Ultimately, this review aims to provide a theoretical foundation and propose novel intervention strategies for the early diagnosis and targeted therapy of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Zunyi Medical University, Zunyi 563000, China.
- Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Zunyi Medical University, Zunyi 563000, China.
- Scientific Research Center, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi 563000, China.
- Department of Nuclear Medicine, The Affiliated Hospital of Zunyi Medical University, Zunyi 563003, China.
ORCID-Profile: Jidong Zhang, Lin Xu, Xianyao Wang
Förderung
- the National Natural Science Foundation of China
- the "12345 Future Talent Training Plan" of Zunyi Medical University
- the Guizhou Provincial Natural Science Foundation
- the Zunyi Science and Technology Bureau
- National Natural Science Foundation of China
- “12345 Future Talent Training Plan” of Zunyi Medical University
- Guizhou Provincial Natural Science Foundation
- Zunyi Science and Technology Bureau
Zitieren
APA
Gan, X., Zhang, L., Yu, T., Jin, S., Wu, Y., Xu, R., Zhang, Y., Zhang, J., Xu, L., & Wang, X. (2026). GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential. Biomolecules, 16(7), 1060. https://doi.org/10.3390/biom16071060
Vancouver
Gan X, Zhang L, Yu T, Jin S, Wu Y, Xu R, et al. GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential. Biomolecules. 2026;16(7):1060. doi:10.3390/biom16071060
BibTeX
@article{Gan2026,
author = {Gan, Xinyun and Zhang, Longze and Yu, Ting and Jin, Sikan and Wu, Yan and Xu, Rui and Zhang, Yaqi and Zhang, Jidong and Xu, Lin and Wang, Xianyao},
title = {GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {7},
pages = {1060},
doi = {10.3390/biom16071060}
}
EUVIMED